Login to Your Account

Other News To Note

Wednesday, October 10, 2012
• AtheroNova Inc., of Irvine, Calif., said it is supporting an additional preclinical study at the David Geffen School of Medicine at the University of California, Los Angeles, to expand the uses of compounds to regress atherosclerotic plaque under its pending patents.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription